Business Paid
Ryvu declares bigger spending in 2019
16:42
One of the largest innovative biotechnology companies in Europe Ryvu Therapeutics increased spending on research and development of new drug candidates. As a result, operating expenses amounted to PLN 79.5 million and increased by 36 percent compared to last year. Investment expenditure (CAPEX) reached PLN 37 million versus PLN 18 million in 2018.
The company actively obtained grant financing. Last year, it recognized nearly PLN 30 million in…
This article is for subscribers
Warsaw Business Journal subscribers get the full archive (12,248 articles going back to 1995) and the print edition.
SubscribeOr try Poland A.M. free for 7 days, the daily briefing, or see all plans and prices.
